Endocrine Peptide Test Market Growth Opportunities: Insights from 2025–2029

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Does The Market Size Of The Endocrine Peptide Test Industry Compare Between 2025 And 2029?

The endocrine peptide test market size has experienced robust expansion in recent years. This market is projected to expand from $9.11 billion in 2024 to reach $9.95 billion by 2025, demonstrating a compound annual growth rate (CAGR) of 9.3%. Historically, this growth has been driven by factors such as increasing government spending, a rising prevalence of diabetes, a global decline in human immunity, an elevated risk of contracting chronic diseases, and an increase in government initiatives.

The market size for endocrine peptide tests is projected to experience robust expansion over the coming years. This market is forecast to reach $13.9 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.7%. Key factors driving this growth during the forecast period include the escalating demand for endocrine peptide tests, increased investment in research and development, a surge in lifestyle-related illnesses, an expanding elderly demographic, and the growing incidence of diabetes across the population. Significant trends anticipated in the same period involve progress in endocrine testing methodologies, innovations in product technologies, intensified research and development efforts aimed at creating new testing solutions, an increasing volume of product approvals, and a general move towards preventive healthcare practices.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16675&type=smp

What Are The Emerging Market Drivers Creating New Opportunities In The Endocrine Peptide Test Industry?

The increasing occurrence of diabetes is anticipated to fuel the expansion of the endocrine peptide test market in the future. Diabetes encompasses various conditions characterized by elevated blood sugar (glucose) levels. The rise in diabetes cases is attributed to factors like poor dietary habits, inactive lifestyles, inherited susceptibility, and an expanding older demographic. Endocrine peptide tests, such as hemoglobin A1c, fasting plasma glucose, and C-peptide assessments, are utilized for diabetes management, including diagnosis, tracking glucose levels, and evaluating insulin generation and responsiveness. As an illustration, in June 2024, data from the National Health Service (NHS), a UK-based government department, indicated a substantial increase in diabetes diagnoses among individuals under 40, growing from 173,166 in 2022 to 216,440 in 2023. This significant surge highlights a worrying pattern of increasing diabetes occurrence among younger age groups. Consequently, the growing incidence of diabetes is a key stimulant for the endocrine peptide test market.

How Is The Endocrine Peptide Test Market Classified Into Different Segments?

The endocrine peptide testmarket covered in this report is segmented –

1) By Test-Type: Dehydroepiandrosterone Sulphate; Progesterone; Luteinizing Hormone; Thyroid Prolactin; Oestradiol; Human Chorionic Gonadotropin; Thyroid-Stimulating Hormone; Other Test-Types

2) By Technology: Mass Spectroscopy; Immunoassay; Chromatography; Nucleic Acid Based; Other Technologies

3) By End-User: Clinics; Healthcare Centers; Hospitals; Commercial Laboratories

Subsegments:

1) By Dehydroepiandrosterone Sulphate (DHEA-S): Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)

2) By Progesterone: Immunoassay Tests; Chemiluminescence Assays; ELISA Tests

3) By Luteinizing Hormone (LH): Immunoassay Tests; Enzyme Immunoassay (EIA); Radioimmunoassay (RIA)

4) By Thyroid Prolactin: Immunoassay Tests; Chemiluminescence Assays; Radioimmunoassay (RIA)

5) By Oestradiol: Immunoassay Tests; Enzyme-Linked Immunosorbent Assay (ELISA); Radioimmunoassay (RIA)

6) By Human Chorionic Gonadotropin (hCG): Immunoassay Tests; Chemiluminescence Assays; Enzyme Immunoassay (EIA)

7) By Thyroid-Stimulating Hormone (TSH): Immunoassay Tests; Radioimmunoassay (RIA); Enzyme-Linked Immunosorbent Assay (ELISA)

8) Other Test-Types: Cortisol; Insulin; Growth Hormone (GH); Parathyroid Hormone (PTH)

Which Ongoing Trends Are Expected To Shape The Endocrine Peptide Test Market Outlook?

Major companies engaged in the endocrine peptide test market are actively creating immunoassay testing systems to elevate the accuracy, sensitivity, and speed of endocrine peptide diagnostics. These systems utilize antibodies for the detection and measurement of specific peptides in either blood or urine specimens, providing healthcare professionals with valuable data on hormone levels and endocrine function. For example, in July 2023, Siemens Healthineers, a German-based healthcare services company, introduced the Atellica CI Analyzer, a compact instrument for immunoassay and clinical chemistry testing, which includes endocrine peptide assays. The analyzer also features a reproductive endocrinology menu offering anti-Mullerian hormone (AMH) to determine ovarian reserve, and sFlt-1 and PlGF (placental growth factor) to assist in the prognosis of preeclampsia. The Atellica CI Analyzer is engineered to produce quality results swiftly and consistently, capable of processing up to 1000 tests per hour, and enhances workflow efficiency and flexibility to support laboratories in meeting their evolving testing demands.

Who Are The Prominent Global Companies Shaping The Endocrine Peptide Test Market?

Major companies operating in the endocrine peptide test market are Siemens AG, F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Merck KGaA, Becton Dickinson and Company, Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Agilent Technologies Inc., Illumina Inc., bioMérieux SA, Bio-Rad Laboratories Inc., DiaSorin S.p.A., Sciex, Bio-Techne Corporation, Invitae Corporation, ARUP Laboratories, Genova Diagnostics, Boston Heart Diagnostics Corporation, Immunodiagnostic Systems Ltd., Mayo Clinic Laboratories

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/endocrine-peptide-test-global-market-report

What Are The Key Regional Factors Influencing The Endocrine Peptide Test Market Growth?

North America was the largest region in the endocrine peptide test market in 2024. The regions covered in the endocrine peptide test market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Endocrine Peptide Test Market Report:

https://www.thebusinessresearchcompany.com/customise?id=16675&type=smp

Browse Through More Reports Similar to the Global Endocrine Peptide Test Market 2025, By The Business Research Company

Biosimilar Therapeutic Peptide Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biosimilar-therapeutic-peptide-global-market-report

Peptide Therapeutics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-therapeutics-global-market-report

Peptide Antibiotics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/peptide-antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795